Symbiotec Pharmalab Limited has announced its financial results for the second quarter (Q2) and first half (H1) of FY27. The company reported a consolidated revenue of ₹280 crore for Q2 FY27, a 43% increase year-on-year. For H1 FY27, revenue stood at ₹498 crore, up 25%. The company also highlighted key business updates in APIs, Complex Injectables, and CDMO services, alongside a ₹1,000+ crore capex investment in new businesses.
Symbiotec Pharmalab Reports Strong Q2 & H1 FY27 Performance
Symbiotec Pharmalab Limited has disclosed its financial performance for the second quarter (Q2) and the first half (H1) of the financial year 2027 (FY27). The company registered a consolidated revenue of ₹280 crore in Q2 FY27, marking a significant year-on-year growth of 43%. For the first half of FY27, the revenue reached ₹498 crore, reflecting a 25% increase compared to the corresponding period.
Key Financial Highlights
The company’s reported EBITDA for Q2 FY27 saw an impressive 82% increase to ₹92 crore, with EBITDA margins at 32.7%. For H1 FY27, reported EBITDA grew to ₹136 crore. Profit After Tax (PAT) for Q2 FY27 stood at ₹52 crore, a substantial 169% rise year-on-year, while H1 FY27 PAT grew by 34% to ₹66 crore.
Strategic Business Updates
In its operational updates, Symbiotec highlighted steady sales growth of 11% in its APIs business for H1 FY27. The company successfully completed four major regulatory audits, including EUGMP and USFDA audits. Under Complex Injectables, a licensing agreement for distribution of two DCV products in the US was signed, with part revenue of ₹53 crore recognized. The company also reported filing its first molecule ANDA for DCV with the USFDA. In CDMO Services, an Industrial Biotech division is advancing with a 10-year take-or-pay agreement and progress in a European partnership. The company also announced plans for a ₹1,000+ crore capex investment in new businesses, with revenue expected to commence in the next 6-12 months.
Investment and Outlook
Symbiotec Pharmalab has outlined its growth strategy, emphasizing its R&D-driven approach, vertically integrated manufacturing, and commitment to compliance. The company’s investment in new technologies and infrastructure is poised to support expansion across its diverse business verticals. Management expressed confidence in the growth outlook and the potential of its emerging businesses, particularly Injectables and CDMO, which are expected to scale significantly.
Source: BSE
